Tag: release

British Novelist Honored at Hôtel Belles Rives for ‘Départ(s)’ at the Prize’s 15th Edition

NEW YORK, June 12, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Wise Group plc (NASDAQ: WSE) resulting from allegations that Wise Group plc may have issued materially misleading business information to the investing public.

NEW YORK, June 12, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Commvault Systems, Inc. (NASDAQ: CVLT) between April 29, 2025 and January 26, 2026, inclusive (the “Class Period”), of the important July 17, 2026 lead plaintiff deadline.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS

NORTH LIBERTY, Iowa, June 12, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Heartland Express, Inc. (Nasdaq: HTLD) announced today the declaration of a regular quarterly cash dividend. The $0.02 per share dividend will be paid on July 6, 2026, to shareholders of record at the close of business on June 23, 2026. We currently estimate that a total of $1.6 million will be paid on the Company's approximate seventy-eight million shares of common stock. This is the Company's ninety-second consecutive quarterly cash dividend. With the payment of this dividend, the Company will have paid a total of $564.5 million in cash dividends, including four special dividends since the dividend program was implemented in the third quarter of 2003.

NEWTOWN, Pa., June 12, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today announced that the planned test of tivoxavir marboxil (TXM) in a Phase 2a human influenza challenge study has been deferred due to a negative review of the program by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA).

Vancouver, BC, June 12, 2026 (GLOBE NEWSWIRE) -- Rocket Doctor AI Inc. (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) (“Rocket Doctor AI”) has granted an aggregate 47,013 stock options, exercisable at $0.71 per share and valid for a term of three years, and an aggregate 514,801 restricted share units, valid for a term between one to three years, to consultants and employees of the Company and its subsidiaries.  The stock options and restricted share units are issued pursuant to the Company’s share compensation plans and are subject to a statutory hold period of four months and one day from issuance, in addition to vesting provisions.

Additionally, and further to the Company’s news release dated July 18, 2025, the Company has extended the marketing services provided by 45 Degrees, Inc. (“45 Degrees”) and Investment Publishing LLC (“Investment Publishing”) to provide digital marketing and investor awareness services until September 30, 2026. No additional compensation shall be payable to 45 Degrees or Investment Publishing for the additional services provided.

SPCH and SSPC provide active traders with cost-effective bullish and bearish daily leveraged exposure to the historic SpaceX IPO

CALGARY, Alberta, June 12, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that the Company has elected to voluntarily delist its common shares from the TSX Venture Exchange (“TSXV”). The Company will provide additional information on timing for the completion of the delisting of its common shares in a separate press release.